Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares are down during Thursday’s premarket league arsenic the institution reported its fourth-quarter and full-year 2025 fiscal results.

Over the past year, the company’s banal has plunged from $106.86 to $18.96, owed to diligent deaths, FDA objective hold, proceedings setbacks, and shipment pause.

On Wednesday, Sarepta Therapeutics reported an adjusted nonaccomplishment of $3.58 per share, missing the Wall Street estimation nonaccomplishment of $1.31. Sales reached $442.93 million, beating the statement of $391.92 million.

Don't Miss:

• Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In astatine $0.85/Share

• Explore the Fire-Safe Energy Storage Company With $185M successful Contracted Revenue

The income fell 33% twelvemonth implicit year, chiefly reflecting $273.8 cardinal little successful nett merchandise gross of Elevidys arsenic a effect of little measurement pursuing the company’s determination to suspend shipments of Elevidys to non-ambulatory patients successful the U.S. successful June 2025.

“Following a tumultuous 2025, we entered 2026 from a presumption of strength… In 2025, we streamlined our operations, delivered beardown revenue, and ended the twelvemonth with astir $1.0 cardinal successful cash, arsenic we expect remaining profitable and cash‑flow affirmative successful 2026. ELEVIDYS has emerged from a challenging twelvemonth with a wide label, accepted support for ambulatory patients, and a program intended to enactment america connected a imaginable pathway backmost to serving the non‑ambulatory community…,” said Doug Ingram, CEO, Sarepta Therapeutics.

In an SEC filing connected Wednesday, Douglas Ingram shared his program to discontinue arsenic Chief Executive Officer by the extremity of 2026 oregon upon the assignment of his replacement. The institution has commenced a search.

Trending: Before the IPO: How One Company Quietly Locked Up 500+ Iconic Character Rights

William Blair connected Thursday wrote “…the Elevidys weakness successful the 4th fourth is not an outlier but was an aboriginal awesome of a materially weaker Elevidys trajectory successful 2026, with Elevidys revenues apt to dip good beneath the $500 million/year level that was reiterated successful January.”

Although the institution has guided for unchangeable PMO gross successful 2026, fixed the caller nonaccomplishment of the ESSENCE trial, expert Sami Corwin is hesitant owed to concerns that Vyondys 53 and Amondys 45 whitethorn suffer their selling authorization.

The expert besides highlights that Dyne Therapeutics Inc. (NASDAQ:DYN) intends to question the accelerated support of its Exon 51 skipper successful the 2nd quarter, which could further interaction Sarepta’s apical line.